Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company is engaged in the identification, development and commercialization of novel drugs that is chiefly intended for the treatment of cancer and related diseases. The Company's lead compound is tesetaxel, a novel taxane compound that is taken by mouth. Tesetaxel has completed Phase II trials in a number of cancer types. Clinical trials conducted by the Company have confirmed that the drug has definite antitumor activity in gastric cancer and breast cancer. Tesetaxel appears to be associated with a substantially lower incidence of side effects, particularly hypersensitivity reactions and peripheral nerve damage, both of which are common side effects of taxanes. The Company's other pipeline project consists of the development of an orally bioavailable gallium-containing compound.